BLIS Technologies Ltd
NZX:BLT
Intrinsic Value
BLIS Technologies Ltd. engages in the development of healthcare products based on strains of bacteria that produce Bacteriocin activity. [ Read More ]
The intrinsic value of one BLT stock under the Base Case scenario is 0.02 NZD. Compared to the current market price of 0.018 NZD, BLIS Technologies Ltd is Undervalued by 12%.
Valuation Backtest
BLIS Technologies Ltd
Run backtest to discover the historical profit from buying and selling BLT stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
BLIS Technologies Ltd
Current Assets | 10m |
Cash & Short-Term Investments | 8m |
Receivables | 996k |
Other Current Assets | 1m |
Non-Current Assets | 1.9m |
PP&E | 973k |
Intangibles | 969k |
Current Liabilities | 1.5m |
Accounts Payable | 1.3m |
Other Current Liabilities | 250k |
Non-Current Liabilities | 270k |
Long-Term Debt | 270k |
Earnings Waterfall
BLIS Technologies Ltd
Revenue
|
10.7m
NZD
|
Operating Expenses
|
-11m
NZD
|
Operating Income
|
-294k
NZD
|
Other Expenses
|
-37k
NZD
|
Net Income
|
-331k
NZD
|
Free Cash Flow Analysis
BLIS Technologies Ltd
BLT Profitability Score
Profitability Due Diligence
BLIS Technologies Ltd's profitability score is 34/100. The higher the profitability score, the more profitable the company is.
Score
BLIS Technologies Ltd's profitability score is 34/100. The higher the profitability score, the more profitable the company is.
BLT Solvency Score
Solvency Due Diligence
BLIS Technologies Ltd's solvency score is 96/100. The higher the solvency score, the more solvent the company is.
Score
BLIS Technologies Ltd's solvency score is 96/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
BLT Price Targets Summary
BLIS Technologies Ltd
Shareholder Return
BLT Price
BLIS Technologies Ltd
Average Annual Return | 9.76% |
Standard Deviation of Annual Returns | 73.91% |
Max Drawdown | -85% |
Market Capitalization | 22.9m NZD |
Shares Outstanding | 1 279 300 000 |
Percentage of Shares Shorted |
N/A
|
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
BLIS Technologies Ltd. engages in the development of healthcare products based on strains of bacteria that produce Bacteriocin activity. The company is headquartered in Dunedin, Otago. The company went IPO on 2001-07-30. The firm is also engaged in supply of healthcare ingredients and the manufacture of part and finished goods and food products for sale in domestic and international markets. The firm supplies BLIS-branded finished goods. The firm's products include BLIS K12 and BLIS M18, which are oral probiotics providing protection for ear, nose and throat health, halitosis (bad breath), gums and teeth health and immune support. The firm distributes its products through Stratum Nutrition in North America, NZPR Group in China, and Bluestone Pharma in Europe and Middle East. Its other BLIS branded products include Throat Guard EVERYDAY BLIS K12, Travel Guard BLIS K12, Fresh Breath Kit K12 and Toddler Protect BLIS K12 Powder for Toddlers.
Contact
IPO
Employees
Officers
The intrinsic value of one BLT stock under the Base Case scenario is 0.02 NZD.
Compared to the current market price of 0.018 NZD, BLIS Technologies Ltd is Undervalued by 12%.